525 results about "Antibody conjugate" patented technology

This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.

Disclosed are lipid nanoparticle (LNP) delivery systems that specifically target T cells. The LNP delivery system comprises antibodies conjugated to the surface of the LNP, e.g., via maleimide chemistry, that target at least two T cell surface proteins, e.g., CD3 and CD28. The LNP delivery system can have a single population of LNP conjugated to either a bispecific antiCD3 / antiCD28 antibody, or two monospecific antiCD3 and antiCD28 antibodies, or two populations of LNP wherein each population comprises a monospecific antibody. The payload of the LNP delivery system can be, e.g., mRNA encoding chimeric antigen receptors (CAR), a linear DNA fragment or a plasmid encoding chimeric antigen receptors (CAR) or therapeutic proteins such as antibodies, components of a gene editing systems (e.g., CRISPR-Cas), small molecules, antibody-drug conjugates (ADC), and any combination thereof, either encapsulated in the LNP or attached to its surface (e.g., conjugated). Also provided are lipids, pharmaceutical compositions, kits, and methods of treatment.

The invention provides a lipidosome STING agonist delivery system based on a PD-L1 antibody as well as a preparation method and application of the lipidosome STING agonist delivery system, and belongs to the technical field of medical biology. Preparing lipidosome by adopting an ethanol injection method and an ammonium sulfate gradient technology; the PD-L1 antibody and the STING agonist can be loaded at the same time; the liposome is prepared by adopting an ethanol injection method and an ammonium sulfate gradient technology, and the STING agonist can be wrapped in the liposome in an active drug loading manner; dSPE-PEG2000-NHS and a PD-L1 antibody are mixed and incubated according to a specific proportion by utilizing a post-insertion method to form an antibody conjugated micelle, and the antibody conjugated micelle is fused with a blank liposome to realize antibody modification; secondly, the nano-liposome has good drug carrier characteristics and can effectively protect the loaded drug, reduce the risk of enzymolysis of the drug and improve the stability of the drug in vivo, so that the liposome drug delivery system simultaneously loading the nano-liposome and the nano-liposome is successfully prepared.

A kit for detecting expression of AIRE and Treg in lymphatic tissue infected by EB virus comprises colloidal quantum well antibody conjugates, including a colloidal quantum well and protein AIRE and GITR conjugates and a colloidal quantum well and antibody CD25 and Foxp3 conjugates. The detection method comprises the following steps: (1) carrying out slicing treatment on a lymphatic tissue, and carrying out antigen repair by using an antigen repair liquid; (2) respectively adding colloidal quantum well proteins or antibodies coupled with different targets to dye the sections; (3) carrying out nucleus staining; and (4) collecting multi-channel fluorescence image information of the tissue slice, and judging expression levels and mutual relations of AIRE, Treg cells and dendritic cells in immune tolerance in combination with spatial positioning and intensity distribution of fluorescence signals of different channels. According to the invention, qualitative or quantitative multi-parameter and high-precision detection of the immune tolerance related cells in the lymph tissue is realized.

The invention provides antibody conjugate compositions of Formula I comprising an antibody linked by conjugation to one or more target protein binder and VHL ligand (TPI-VHL) moieties. The invention also provides TPI-VHL derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the antibody conjugates through a linker or linking moiety. The invention further provides methods of treating diseases and disorders such as cancer with the antibody conjugates.

Provided herein are methods for reducing the likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual being treated with an antibody-drug conjugate (ADC). Also provided herein are methods for increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual. In some embodiments, the methods comprise administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function. Compositions, uses, and kits related thereto are also provided.

Provided are a blocking type GIPR antibody, an antigen-binding fragment thereof, an antibody conjugate thereof, and use thereof in preparing a medicament. The GIPR antibody and the antigen-binding fragment thereof have a relatively high affinity for GIPR protein and bind to the GIPR protein expressed on the cell surface, blocking the cell-activating activity of GIP. The GIPR antibody has relatively good cellular internalization activity. Pharmacokinetic research shows that the GIPR antibody and the antigen-binding fragment thereof exhibit relatively good stability in mice, with an AUC0-t up to 15,033.01 hour × μg / mL. The antibody conjugate prepared by adopting the GIPR antibody shows stable and lasting activity in reducing the weight of laboratory animal models and therefore has wide application prospects.

The present disclosure relates to improved linkers for conjugating oligonucleotidebased agents (e.g., RNAi agents) to an antibody or antibody fragment (e.g., anti-transferrin receptor (TfR1) antibodies or fragments).

The present disclosure relates to proteomics, including the detection of immune cell target proteins as examples that the disclosed methods can be used for protein detection. Methods, compositions, and systems are described for identifying the presence of proteins, including detecting immune cell proteins from a sample using a combination of multiplex immuno-PCR with antibodies conjugated to oligonucleotides comprising an antibody-specific barcode flanked by PCR priming sites; detection of barcoded amplicons obtained from immuno-PCR with encoded padlock probes comprising codes specific for the barcodes / target protein; rolling circle amplification (RCA) of the circularized padlock probes; and determination of the sequence of the codes amplified by RCA by next generation sequencing or using fluorescently labeled hybridization probes.

The present disclosure relates to antibodies and antibody conjugates that selectively bind to TROP2 and its isoforms and homologs, and compositions comprising the antibodies and antibody conjugates. Also provided are methods of using the antibodies and compositions, such as therapeutic and diagnostic methods.

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.

The present invention relates to an antibody or an antigen-binding fragment thereof comprising a single domain antibody specifically binding to mesothelin, an antibody conjugate comprising same, a pharmaceutical composition for preventing or treating cancer or a tumor, and a composition for diagnosing or monitoring cancer or a tumor. When the antibody or composition comprising same is used, mesothelin-related cancer or tumors can be effectively prevented, treated, or diagnosed.

The invention relates to antibody conjugates (e.g., a bispecific antibody), drug and nanoparticle compositions and methods and compositions for generating them. This invention further relates to methods of using these compositions for imaging, diagnosing or treating a disease.

The present invention relates to an anti-HER3 dual payload antibody-drug conjugate (HER3-dpADC) having a structure of formula (I), and a preparation method therefor and the use thereof, wherein the dual loads comprise a topoisomerase inhibitor and a tyrosine kinase inhibitor, respectively.

The present disclosure relates to molecules binding to delta-like ligand 3 (DLL3), such as anti-DLL3 chimeric antigen receptors (CARs), anti-DLL3 antibodies including antigen binding domains, bispecific antibodies, antibody conjugates, anti-DLL3 immune cell engagers, and other fusion proteins comprising anti-DLL3 antigen binding domains, and the like, polynucleotides and vectors encoding DLL3 binding molecules, and engineered cells expressing DLL3 binding proteins, and methods of making and using the DLL3 binding proteins.

The invention discloses a time-space controllable T cell adapter based on a DNA nanostructure as well as a construction method and application of the time-space controllable T cell adapter, and belongs to the field of DNA nanotechnology. The T cell adapter comprises a six-spiral-bundle paper folding structure, and an internal functional layer and an external shielding layer which are assembled on the six-spiral-bundle paper folding structure; the six-spiral bundle paper folding structure is formed by assembling 63 staple chains and M13 in total; the internal functional layer comprises nucleic acid-antibody conjugates which are combined on four spiral extension sequences at the top and the bottom of the six-spiral bundle origami structure, and hand-in-hand palindromic sequences which are combined on two spiral extension sequences at the left side and the right side; the outer shielding layer comprises a C-chain modified serum albumin binding peptide and a chain I, and the chain I comprises a pH-responsive i-motif switch. The T cell adapter disclosed by the invention has the space-time control capability of pH response and the potential of inducing TCR clustering to enhance T cell activation, and has huge potential in the aspect of improving the safety and effectiveness of T cell immunotherapy.

The present invention relates to antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular tumor cells. An antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus semiaquilaria, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine dimer or a pyrrolo-benzodiazepine dimer (PBD), and an analog or prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

Disclosed herein are antibodies, agonist peptides, and dual agonist peptides. Further disclosed herein are antibody conjugates comprising the antibodies, agonist peptides, and / or dual agonist peptides disclosed herein. In some embodiments, the antibodies or antibody conjugates of the invention may be used to treat metabolic diseases.

Disclosed are lipid nanoparticle (LNP) delivery systems that specifically target T cells. The LNP delivery system comprises antibodies conjugated to the surface of the LNP, e.g., via maleimide chemistry, that target at least two T cell surface proteins, e.g., CD3 and CD28. The LNP delivery system can have a single population of LNP conjugated to either a bispecific antiCD3 / antiCD28 antibody, or two monospecific antiCD3 and antiCD28 antibodies, or two populations of LNP wherein each population comprises a monospecific antibody. The payload of the LNP delivery system can be, e.g., mRNA encoding chimeric antigen receptors (CAR), a linear DNA fragment or a plasmid encoding chimeric antigen receptors (CAR) or therapeutic proteins such as antibodies, components of a gene editing systems (e.g., CRISPR-Cas), small molecules, antibody-drug conjugates (ADC), and any combination thereof, either encapsulated in the LNP or attached to its surface (e.g., conjugated). Also provided are lipids, pharmaceutical compositions, kits, and methods of treatment.

The invention provides a method for simultaneously detecting the purity of an antibody conjugate and the coupling ratio of a drug antibody based on a size exclusion chromatography method and application of the method. The method comprises the following steps: detecting and analyzing the purity of an ADC (Analog to Digital Converter) sample to be detected and the coupling ratio of the drug antibody by adopting an SEC-UPLC (Single Emission Computation-Ultra Performance Liquid Chromatography) serially connected with an ultraviolet detector; collecting a signal of the sample under the antibody characteristic ultraviolet absorption wavelength and the small molecule characteristic ultraviolet absorption wavelength at the same time; calculating the DAR value and the monomer purity of the ADC molecule according to the chromatographic absorption peak area; a mobile phase adopted by the SEC-UPLC is a sodium chloride-phosphate buffer solution containing 0-10vol% of an organic solvent; the ADC sample to be detected is an ADC molecule coupled with Dxd type small molecules. The invention provides an analysis method which is widely applicable to determination of the DAR value and the monomer purity of the ADC molecule coupled with the Dxd small molecules. The method can simultaneously solve the problems that the DAR value detection and analysis flux of the Dxd small molecules is low and the applicability is limited.

The present invention relates to FcRH5 binding domains. In particular, the invention provides single domain antibodies, antibody conjugates, chimeric antigen receptors (CARs) and immune cell engagers which comprise such binding domains.

Provided herein are cerebron degrading agent antibody conjugates (cDACs) comprising a cerebron degrading agent moiety covalently linked to an antibody. The cDACs target proteins for intracellular degradation and can be used to treat diseases and conditions.

Described herein are anti-MUC1* antibodies or antibody fragments and antibody drug complex (ADC) comprising an anti-MUC1* antibody conjugated via a linker to a toxin. The present disclosure also provides compositions comprising the antibodies and antibody drug complexes and methods for treating diseases and disorders such as cancer.

The present invention relates to antibodies, such as full-length antibodies or antigen-binding fragments thereof, that specifically bind to BCMA (B-cell maturation antigen) and CD3 (cluster of differentiation 3). The present invention also relates to antibody conjugates (e.g., antigen-drug-conjugates) comprising BCMA antibodies, compositions comprising BCMA antibodies, and methods of using BCMA antibodies and their conjugates to treat disease conditions associated with cells expressing BCMA (e.g., cancer or autoimmune diseases). The present invention further relates to heteromultimeric antibodies that specifically bind to CD3 and tumor cell antigens (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for preparing and purifying such heterodimeric antibodies, and their use in diagnosis and treatment are also provided.

According to the invention, IN10018 and a macromolecular drug are combined to treat tumors, and the macromolecular drug is a monoclonal antibody, a bispecific antibody or an antibody conjugate.

The present disclosure provides a method for preparing an antibody-drug conjugate, wherein the antibody-drug conjugate is subjected to site-specific conjugation, based on an N-glycosylation site in an Fc region of an antibody, and the method includes the steps of: (1) providing a donor containing oxazoline oligosaccharide, an antibody containing a GlcNAc motif, and an immobilized endoglycosidase with glycosyltransferase activity; (2) covalently attaching the activated donor containing the oxazoline oligosaccharide to the antibody containing the GlcNAc motif under the catalysis of the endoglycosidase. The present disclosure further relates to an endoglycosidase fusion protein, including the endoglycosidase, a Halo tag, and / or a His tag that are covalently attached. The present disclosure further relates to an immobilized endoglycosidase fusion protein obtained by immobilizing the endoglycosidase fusion protein on a support, and a prepacked column filled with the immobilized fusion protein, as well as use of the immobilized endoglycosidase fusion protein for purification of an antibody conjugate.

The present disclosure relates to antibodies and antibody conjugates having one or more site-specific mutations in the CH2 domain of the heavy chain. The antibody variants disclosed herein can have improved characteristics (e.g., thermal stability, antibody yields, antibody titers, cell-killing) relative to a parent or wild type antibody, including aglycosylated parent or wild type antibodies. Pharmaceutical compositions, diagnostic compositions and kits comprising the same, as well as methods of using these compositions and kits for therapeutic and diagnostic purposes, are also described.

Disclosed herein, in certain embodiments, are anti-hCCR8 antibodies, anti-hCCR8 antibody conjugates, and pharmaceutical compositions which comprise the anti-hCCR8 antibodies or conjugates. In some embodiments, also disclosed herein are methods of delivering a payload utilizing an anti-hCCR8 antibody described herein, and methods of treatment with use of an anti-hCCR8 antibody described herein.

The invention discloses a conjugate with a targeting effect and a preparation method and application thereof, the conjugate has a structure shown in a formula Ab-[M-L-E-D] x, a drug is selected from a DNA topoisomerase inhibitor, and the prepared antibody drug conjugate has a better drug-antibody coupling ratio and has an excellent targeting killing effect on solid tumors such as gastric cancer, breast cancer, lung cancer and urothelial cancer.

A conjugate contains an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking the amatoxin and said CD37-binding moiety, and the conjugate is prepared in a synthesis method. A pharmaceutical composition contains the conjugate for use in the treatment of immune cell-, particularly B-cell and / or lymphoma associated diseases and / or malignancies.